公司简介
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia ...
关联新闻
- Novartis bets on bigger blockbusters to power growth, forecasting 5% annual sales through 2031
Ahead of its Capital Markets Day on Thursday, Novartis upgraded its peak sales outlook for three of its blockbuster drugs to a combined $18 billion, up from a previous forecast of a combined $14 billi...
- Novartis Sees Sales Growth Through 2031
The drugmaker expects annual sales growth of 5% from 2026 to 2031, from a previous forecast of 5% to 6% over the 2025-30 period.
- Novartis targets 5% annual sales growth through 2031
Swiss drugmaker Novartis set a target of annual sales growth of 5% through 2031 on Thursday, relying on a handful of drugs already on the market to offset looming patent expiries and recover from a s...
- A failed trial for a heart drug casts shadow over rivals developing similar therapies
The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels.
- 6 dividend stocks for investors who want to cut their exposure to the S&P 500
Novartis, Mitsubishi and Canadian Natural are examples of companies in developed markets outside the U.S. that pass screens for high dividend yields and low volatility for prices and earnings.
- Companies promised AI gains— here's how the payoff showed up in earnings
Companies including Santander, Novartis and Standard Chartered say artificial intelligence is beginning to contribute to revenue, costs or profitability. Santander said AI initiatives generated 194 mi...
- Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Swiss drugmaker Novartis' oral multiple sclerosis (MS) drug remibrutinib meaningfully reduced relapses in patients, according to data presented at a medical conference in Toronto on Friday, but less ...
- Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a serious kidney condition, citing "strategic considerations", according to a federal clinical tr...